Evaluating the Role of Clozapine in Treatment-Resistant Schizophrenia: A Narrative Synthesis of Clinical, Economic, and Quality-of-Life Outcomes.

Treatment-resistant schizophrenia (TRS) affects up to 30% of individuals with schizophrenia who fail to respond to standard antipsychotics. This narrative review summarizes current evidence on clozapine's clinical effectiveness, economic impact, and quality-of-life benefits. A nonsystematic literature review of PubMed, Scopus, and Google Scholar was performed using relevant clinical and health-economic keywords. Findings consistently demonstrate that clozapine provides superior symptom reduction, reduces rehospitalization and mortality, and improves functional recovery and patient-reported outcomes. Evidence from real-world studies and meta-analyses shows marked reductions in rehospitalization rates, mortality, and caregiver burden compared with other antipsychotics. Economic analyses confirm that, although clozapine requires ongoing hematologic monitoring, its long-term savings from reduced inpatient care, emergency visits, and indirect productivity losses outweigh these costs, establishing its cost-effectiveness across diverse health-system settings. Despite its proven benefits, clozapine remains underused due to safety concerns, mandatory monitoring, limited prescriber confidence, and infrastructural barriers. Optimizing its use requires early identification of TRS, timely initiation of therapy, individualized monitoring strategies, and close interprofessional collaboration among psychiatrists, pharmacists, and healthcare teams. At the policy level, investment in laboratory infrastructure, subsidized monitoring programs, and the development of locally adapted treatment guidelines are critical to expanding safe, equitable, and sustainable access to clozapine worldwide.